Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Diverse Psychotomimetics Act Through a Common Signaling Pathway
Per Svenningsson,1
Eleni T. Tzavara,2
Robert Carruthers,1
Ilan Rachleff,1
Sigrid Wattler,3
Michael Nehls,3
David L. McKinzie,2
Allen A. Fienberg,1,4
George G. Nomikos,2
Paul Greengard1*
Abstract:
Three distinct classes of drugs: dopaminergic agonists (suchas D-amphetamine), serotonergic agonists (such as LSD), andglutamatergic antagonists (such as PCP) all induce psychotomimeticstates in experimental animals that closely resemble schizophreniasymptoms in humans. Here we implicate a common signaling pathwayin mediating these effects. In this pathway, dopamine- and anadenosine 3',5'-monophosphate (cAMP)regulated phospho-proteinof 32 kilodaltons (DARPP-32) is phosphorylated or dephosphorylatedat three sites, in a pattern predicted to cause a synergisticinhibition of protein phosphatase1 and concomitant regulationof its downstream effector proteins glycogen synthesis kinase3(GSK-3), cAMP response elementbinding protein (CREB),and c-Fos. In mice with a genetic deletion of DARPP-32 or withpoint mutations in phosphorylation sites of DARPP-32, the effectsof D-amphetamine, LSD, and PCP on two behavioral parameterssensorimotorgating and repetitive movementswere strongly attenuated.
1 Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, NY 10021, USA. 2 Eli Lilly and Company, Lilly Corporate Center, Neuroscience Discovery Research, Indianapolis, IN 462850510, USA. 3 Lexicon Genetics Inc., The Woodlands, TX 773811160, USA. 4 Intra-Cellular Therapies Inc., Audubon Biomedical Science and Technology Park, New York, NY 10032, USA.
* To whom correspondence should be addressed. E-mail: greengd{at}mail.rockefeller.edu
The editors suggest the following Related Resources on Science sites:
Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism.
E. Santini, M. Feyder, G. Gangarossa, H. S. Bateup, P. Greengard, and G. Fisone (2012)
J. Biol. Chem.
287, 27806-27812
|Abstract »|Full Text »|PDF »
Salt appetite and addiction--unholy twins?.
E. Ritz (2012)
Nephrol. Dial. Transplant.
27, 2146-2148
|Full Text »|PDF »
Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice.
M. A. Pouladi, L. M. Stanek, Y. Xie, S. Franciosi, A. L. Southwell, Y. Deng, S. Butland, W. Zhang, S. H. Cheng, L. S. Shihabuddin, et al. (2012)
Hum. Mol. Genet.
21, 2219-2232
|Abstract »|Full Text »|PDF »
Relation of addiction genes to hypothalamic gene changes subserving genesis and gratification of a classic instinct, sodium appetite.
W. B. Liedtke, M. J. McKinley, L. L. Walker, H. Zhang, A. R. Pfenning, J. Drago, S. J. Hochendoner, D. L. Hilton, A. J. Lawrence, and D. A. Denton (2011)
PNAS
108, 12509-12514
|Abstract »|Full Text »|PDF »
The Physiology, Signaling, and Pharmacology of Dopamine Receptors.
Signaling Pathways Leading to Phosphorylation of Akt and GSK-3{beta} by Activation of Cloned Human and Rat Cerebral D2 and D3 Receptors.
C. Mannoury la Cour, M.-J. Salles, V. Pasteau, and M. J. Millan (2011)
Mol. Pharmacol.
79, 91-105
|Abstract »|Full Text »|PDF »
Role of Aberrant Striatal Dopamine D1 Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine.
F. Napolitano, A. Bonito-Oliva, M. Federici, M. Carta, F. Errico, S. Magara, G. Martella, R. Nistico, D. Centonze, A. Pisani, et al. (2010)
J. Neurosci.
30, 11043-11056
|Abstract »|Full Text »|PDF »
Protein Phosphatase 2A and Glycogen Synthase Kinase 3 Signaling Modulate Prepulse Inhibition of the Acoustic Startle Response by Altering Cortical M-Type Potassium Channel Activity.
D. Kapfhamer, K. H. Berger, F. W. Hopf, T. Seif, V. Kharazia, A. Bonci, and U. Heberlein (2010)
J. Neurosci.
30, 8830-8840
|Abstract »|Full Text »|PDF »
ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities.
F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P. J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, et al. (2008)
J. Pharmacol. Exp. Ther.
327, 827-839
|Abstract »|Full Text »|PDF »
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection.
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al. (2008)
Pharmacol. Rev.
60, 358-403
|Abstract »|Full Text »|PDF »
Dopamine Modulation of Prefrontal Cortex Interneurons Occurs Independently of DARPP-32.
H. Trantham-Davidson, S. Kroner, and J. K. Seamans (2008)
Cereb Cortex
18, 951-958
|Abstract »|Full Text »|PDF »
The B''/PR72 subunit mediates Ca2+-dependent dephosphorylation of DARPP-32 by protein phosphatase 2A.
J.-H. Ahn, J. Y. Sung, T. McAvoy, A. Nishi, V. Janssens, J. Goris, P. Greengard, and A. C. Nairn (2007)
PNAS
104, 9876-9881
|Abstract »|Full Text »|PDF »
From prediction error to psychosis: ketamine as a pharmacological model of delusions.
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?.
C. H. Large (2007)
J Psychopharmacol
21, 283-301
|Abstract »|PDF »
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation.
P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard (2007)
J. Neurosci.
27, 4201-4209
|Abstract »|Full Text »|PDF »
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56{delta} subunit.
J.-H. Ahn, T. McAvoy, S. V. Rakhilin, A. Nishi, P. Greengard, and A. C. Nairn (2007)
PNAS
104, 2979-2984
|Abstract »|Full Text »|PDF »
DARPP-32 Involvement in the Photic Pathway of the Circadian System.
L. Yan, J. M. Bobula, P. Svenningsson, P. Greengard, and R. Silver (2006)
J. Neurosci.
26, 9434-9438
|Abstract »|Full Text »|PDF »
Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32..
Y. Zhang, P. Svenningsson, R. Picetti, S. D. Schlussman, A. C. Nairn, A. Ho, P. Greengard, and M. J. Kreek (2006)
J. Neurosci.
26, 2645-2651
|Abstract »|Full Text »|PDF »
Cannabinoid Action Depends on Phosphorylation of Dopamine- and cAMP-Regulated Phosphoprotein of 32 kDa at the Protein Kinase A Site in Striatal Projection Neurons.
M. Andersson, A. Usiello, A. Borgkvist, L. Pozzi, C. Dominguez, A. A. Fienberg, P. Svenningsson, B. B. Fredholm, E. Borrelli, P. Greengard, et al. (2005)
J. Neurosci.
25, 8432-8438
|Abstract »|Full Text »|PDF »
cAMP and Extracellular Signal-Regulated Kinase Signaling in Response to D-Amphetamine and Methylphenidate in the Prefrontal Cortex in Vivo: Role of {beta}1-Adrenoceptors.
V. Pascoli, E. Valjent, A.-G. Corbille, J.-C. Corvol, J.-P. Tassin, J.-A. Girault, and D. Herve (2005)
Mol. Pharmacol.
68, 421-429
|Abstract »|Full Text »|PDF »
Predictors of schizophrenia--a review.
P. Maki, J. Veijola, P. B. Jones, G. K. Murray, H. Koponen, P. Tienari, J. Miettunen, P. Tanskanen, K.-E. Wahlberg, J. Koskinen, et al. (2005)
Br. Med. Bull.
73-74, 1-15
|Abstract »|Full Text »|PDF »
From The Cover: Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum.
E. Valjent, V. Pascoli, P. Svenningsson, S. Paul, H. Enslen, J.-C. Corvol, A. Stipanovich, J. Caboche, P. J. Lombroso, A. C. Nairn, et al. (2005)
PNAS
102, 491-496
|Abstract »|Full Text »|PDF »
Ethologically Based Resolution of D2-Like Dopamine Receptor Agonist-versus Antagonist-Induced Behavioral Topography in Dopamine- and Adenosine 3',5'-Monophosphate-Regulated Phosphoprotein of 32 kDa "Knockout" Mutants Congenic on the C57BL/6 Genetic Background.
R. E. Nally, A. Kinsella, O. Tighe, D. T. Croke, A. A. Fienberg, P. Greengard, and J. L. Waddington (2004)
J. Pharmacol. Exp. Ther.
310, 1281-1287
|Abstract »|Full Text »|PDF »
Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway".
Response to Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway".
P. Svenningsson, G. G. Nomikos, and P. Greengard (2004)
Science
305, 180d
|Full Text »|PDF »
Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins.
P. B. Allen, A. T. Greenfield, P. Svenningsson, D. C. Haspeslagh, and P. Greengard (2004)
PNAS
101, 7187-7192
|Abstract »|Full Text »|PDF »
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade.
J.-M. Beaulieu, T. D. Sotnikova, W.-D. Yao, L. Kockeritz, J. R. Woodgett, R. R. Gainetdinov, and M. G. Caron (2004)
PNAS
101, 5099-5104
|Abstract »|Full Text »|PDF »
Cyclin-dependent kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum.